Document:

EX-10.8

 Exhibit 10.8 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE
COMPETITIVE HARM IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. 
 Amendment No. 1 to the Amended and
Restated Purchase and Sale Agreement 
 This Amendment No. 1 (“Amendment”) to the Amended and Restated Purchase and Sale Agreement dated
November 24, 2014 (“Purchase and Sale Agreement”) is entered into by and between Cystic Fibrosis Foundation Therapeutics, Inc. (“Seller”) and RPI Finance Trust (“Purchaser”) on this 13th day of October 2016 (“Amendment Effective Date”). Unless otherwise specified, the capitalized terms used in this Amendment shall have the same meaning as in the Purchase and Sale
Agreement. 
 RECITAL: Purchaser and Seller entered into the Purchase and Sale Agreement pursuant to which Purchaser purchased certain royalty
interests owed to Seller by Counterparty under the Counterparty Agreement. On the Amendment Effective Date, Seller and Purchaser also agreed to Amendment No. 7 to the Counterparty Agreement (as in effect on the date hereof, “Amendment
7”), which both Seller and Purchaser have executed, and Seller and Counterparty entered into the Research and Development Award Agreement (as in effect on the date hereof, the “Award Agreement”), which are attached to this Amendment
as Exhibits A and B, respectively. In addition, Purchaser has agreed to [***], as provided in the letter agreement attached to this Amendment as Exhibit C. In addition, the Cystic Fibrosis Foundation (“CFF”), an affiliate of Seller, and
Counterparty have entered into the Data License Agreement as in effect on the date hereof (the “Data License Agreement”), a copy of which is attached hereto as Exhibit D. Exhibits A, B, C and D are referred to collectively as the [***].

 NOW THEREFORE, for good and valuable consideration, the sufficiency of which is acknowledged by the parties hereto, Seller and Purchaser hereby agree to
the following amendments to the Purchase and Sale Agreement: 
  

	1.	 Annual Sales Threshold. The definition of “Annual Sales Threshold” in Section 1 of the
Purchase and Sale Agreement is hereby amended by deleting “$5,000,000,000” and inserting in lieu thereof “$5,800,000,000.” 

  

	2.	 Additions to Purchase Price. Section 2.2 of the Purchase and Sale Agreement is hereby amended by
deleting the first sentence thereof and inserting in lieu thereof the following: 

 “Purchase Price and Additional
Purchase Price. Except as provided in the following sentence, in full consideration for the sale, contribution, assignment, transfer, conveyance and granting of the Purchased Assets, and subject to the terms and conditions set forth herein, the
Purchaser shall pay (or cause to be paid) (i) to the Seller, or the Seller’s designee, by 10:30 a.m. EST on the Closing Date, the sum of $3,300,000,000, in immediately available funds by wire transfer to the

 
Seller Account (the “Initial Purchase Price”) and (ii) shall pay (or cause to be paid) to the Seller the Excess Royalties (any such amounts, the “Additional Purchase
Price,” and collectively with the Initial Purchase Price, the “Purchase Price”). In addition, Purchaser shall also pay to Seller, which amounts shall also constitute “Additional Purchase Price”: 

 

	 	(a)	 Within 5 days of the Amendment Effective Date, [***]. 

 

	 	(b)	 For so long as Seller is obligated to and does make to Vertex the payments called for by Section 7.2 of
Amendment 7, (a) Purchaser will pay to Seller [***] and (b) Seller will promptly (and in any case within five Business Days after receipt from Vertex) provide to RP a true and complete copy of the summary report and certification that Vertex
delivers to Seller pursuant to the last sentence of Section 7.2 of Amendment 7 in respect of the upcoming quarter. 

  

	 	(c)	 [***] of the amounts payable under Section 2.2A of the Purchase and Sale Agreement 

 

	 	(d)	 [***] amounts payable under Section 2.2B of the Purchase and Sale Agreement.” 

 

	3.	 Additional Payments. Section 2.2 of the Purchase and Sale Agreement is hereby amended by inserting
the following Sections 2.2A and 2.2B at the end thereof: 

 “Section 2.2A [***] 

 

	 	(a)	 For so long as Seller is obligated to make payments to Vertex pursuant to Section 2.1 or 2.2 of the Award
Agreement, (i) beginning on [***], Purchaser shall [***] and (ii) Seller will promptly (and in any event within five Business Days after receipt from Vertex) provide to RP a true and complete copy of the summary report and certification
that Vertex delivers to Seller pursuant to the second sentence of each of Sections 2.1 and 2.2 of the Award Agreement in respect of the upcoming quarter. The parties hereto acknowledge and agree that [***]. 

 

	 	(b)	 Seller shall (i) [***], and in any event no later than five Business Days following any receipt thereof by
the Seller and (ii) deliver to Purchaser promptly (and in any event within five Business Days after receipt by Seller) a copy of the royalty reports specified in Section 3.3 of the Award Agreement. Seller’s obligations under this
subpart (b) of Section 2A shall survive termination of the Purchase and Sale Agreement. 

	 	(c)	 The Seller shall perform and comply in all material respects with its duties and obligations under the Award
Agreement. If Seller acquires Knowledge of a matter that constitutes a material breach (or with the giving of notice or the passage of time, or both, would constitute a material breach) under the Award Agreement, Seller shall promptly notify
Purchaser thereof and, after consultation with Purchaser, take (or refrain from taking) reasonable actions to comply or enforce compliance with the Award Agreement.” 

Section 2.2B License. 
  

	 	(a)	 Notwithstanding the second sentence of this Amendment, capitalized terms used in Section 2.2B(b) shall
have the same meaning as in the Data License Agreement. 

  

	 	(b)	 For so long as Vertex is obligated to [***], RP shall [***]. [***]. RP’s obligations pursuant to this
Section 2.2B shall terminate if and when [***]. 

  

	 	(c)	 CFF shall perform and comply in all material respects with its duties and obligations under the Data License
Agreement. If CFF acquires knowledge of a matter that constitutes a material breach (or with the giving of notice or the passage of time, or both, would constitute a material breach) under the Data License Agreement, CFF shall promptly notify
Purchaser thereof and, after consultation with Purchaser, CFF take (or refrain from taking) reasonable actions to comply or enforce compliance with the Data License Agreement.” 

 

	4.	 Payments. All payments hereunder shall be made in immediately available funds by wire transfer to an
account designated by Seller or Purchaser, as the case may be. 

  

	5.	 Financing Statements. Amended and restated financing statements of each of Purchaser and Seller
contemplated by Sections 2.1(c), 2.1(e) and 2.1(f) of the Purchase and Sale Agreement are attached hereto as Exhibits E and F, respectively. 

  

	6.	 Mutual Release. Seller and Purchaser hereby release each other, and each other’s affiliates,
predecessors, successors, assigns, and the directors, trustees, officers, employees, of each (collectively the “Releasees”) from any claim Seller or Purchaser may have against the other and/ or their respective Releasees that may arise out
of the dispute resolved by the [***], provided that the foregoing shall not prevent or impair the Purchaser’s or Seller’s right to bring a claim against the other for any breach of their respective obligations under the Purchase and Sale
Agreement, as amended by this Amendment. 

	7.	 Other Provisions. Except as amended by this Amendment, the Purchase and Sale Agreement is unchanged and
remains in full force and effect. 

  

	8.	 Trustee Capacity of Wilmington Trust Company. Notwithstanding anything contained herein to the contrary,
it is expressly understood and agreed by the parties hereto that (i) this Amendment is executed and delivered by Wilmington Trust Company, not individually or personally but solely in its trustee capacity, in the exercise of the powers and
authority conferred and vested in it under the trust agreement of the Purchaser, (ii) each of the representations, undertakings and agreements herein made on the part of the Purchaser is made and intended not as a personal representation,
undertaking and agreement by Wilmington Trust Company but is made and intended for the purpose of binding only the Purchaser and (iii) under no circumstances shall Wilmington Trust Company be personally liable for the payment of any
indebtedness or expenses of the Purchaser or be liable for the breach or failure of any obligation, representation, warranty or covenant made or undertaken by the Purchaser under this Amendment or any related documents. 

[SIGNATURE PAGE FOLLOWS] 

 In Witness Whereof, Seller and Purchaser have entered into this Amendment by their duly authorized
representatives as of the Amendment Effective Date. 
  

									
	 RPI Finance Trust 

  

By: Wilmington Trust Company, not in its individual capacity but solely in its capacity as owner trustee
	  	    	  	Cystic Fibrosis Therapeutics, Inc.
					
	By:	 	 /s/ Eric A. Kardash
	  		  	By:	 	 /s/ P.W. Campbell

	Name:	 	Eric A. Kardash	  		  	Name:	 	P.W. Campbell
	Title:	 	Assistant Vice President	  		  	Title:	 	President & CEO

 Cystic Fibrosis Foundation (solely with respect to Section 2.2B of Paragraph 3 of this Amendment) 

 

			
	By:	 	 /s/ P.W. Campbell

	Name:	 	P.W. Campbell
	Title:	 	President & CEOExhibit 10.1

 

AMENDMENT

TO THE

INVESTMENT MANAGEMENT TRUST AGREEMENT

 

This Amendment No. 2 (this “Amendment”), dated as
of May 29, 2020, to the Investment Management Trust Agreement (as defined below) is made by and between Trident Acquisitions Corp.
(the “Company”) and Continental Stock Transfer & Trust Company, as trustee (“Trustee”). All terms used
but not defined herein shall have the meanings assigned to them in the Trust Agreement.

 

WHEREAS, the Company and the Trustee entered into an Investment
Management Trust Agreement dated as of May 29, 2018, as amended pursuant to that certain Amendment No. 1 to the Trust Agreement
dated as of November 27, 2019 (as amended, the “Trust Agreement”);

 

WHEREAS, Section 1(i) of the Trust Agreement sets forth the
terms that govern the liquidation of the Trust Account under the circumstances described therein;

 

WHEREAS, at a special meeting of stockholders of the Company
held on May 28, 2020, the Company’s stockholders approved (i) a proposal to amend (the “Charter Amendment”) the
Company’s amended and restated certificate of incorporation, as amended, to provide that the date by which the Company shall
be required to effect a Business Combination to be extended for an additional three months, and (ii) a proposal to extend the date
on which to commence liquidating the Trust Account in the event the Company has not consummated a business combination; and

 

WHEREAS, on the date hereof, the Company is filing the Charter
Amendment with the Secretary of State of the State of Delaware.

 

NOW THEREFORE, IT IS AGREED:

 

1. Section 1(i) of the Trust Agreement is hereby amended and
restated to read in full as follows:

 

“(i) Commence liquidation of the Trust Account
only after and promptly after receipt of, and only in accordance with, the terms of a letter (“Termination Letter”),
in a form substantially similar to that attached hereto as either Exhibit A or Exhibit B, signed on behalf of the Company by its
President, Chief Executive Officer or Chairman of the Board and Secretary or Assistant Secretary, and complete the liquidation
of the Trust Account and distribute the Property in the Trust Account only as directed in the Termination Letter and the other
documents referred to therein; provided, however, that in the event that a Termination Letter has not been received by the Trustee
by the 24-month anniversary of the closing of the IPO (“Closing”) or, in the event that the Company extended the time
to complete the Business Combination for an additional 3-month period by depositing $0.15 for each public share of common stock
that has not redeemed into the trust account, for up to 27-months from the closing of the IPO, but has not completed the Business
Combination within the applicable monthly anniversary of the Closing (“Last Date”), the Trust Account shall be liquidated
in accordance with the procedures set forth in the Termination Letter attached as Exhibit B hereto and distributed to the Public
Shareholders as of the Last Date.”

 

2. All other provisions of the Trust Agreement shall remain
unaffected by the terms hereof.

 

3. This Amendment may be signed in any number of counterparts,
each of which shall be an original and all of which shall be deemed to be one and the same instrument, with the same effect as
if the signatures thereto and hereto were upon the same instrument. A facsimile signature shall be deemed to be an original signature
for purposes of this Amendment.

 

4. This Amendment is intended to be in full compliance with
the requirements for an Amendment to the Trust Agreement as required by Section 7(c) of the Trust Agreement, and every defect in
fulfilling such requirements for an effective amendment to the Trust Agreement is hereby ratified, intentionally waived and relinquished
by all parties hereto.

 

5. This Amendment shall be governed by and construed and enforced
in accordance with the laws of the State of New York, without giving effect to conflicts of law principles that would result in
the application of the substantive laws of another jurisdiction.

 

[Signature Page Follows]

 

     

     

    

 

IN WITNESS WHEREOF, the parties have duly executed this 2nd
Amendment to the Investment Management Trust Agreement as of the date first written above.

 

CONTINENTAL STOCK TRANSFER & TRUST COMPANY, AS TRUSTEE

 

	By:	/s/ Francis Wolf	 
	Name:  	Francis Wolf	 
	Title:	Vice President	 

 

TRIDENT ACQUISITIONS CORP.

  

	By:	/s/ Vadim Komissarov	 
	Name:  	Vadim Komissarov	 
	Title:	President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]